American Chemical Society 232nd National Meeting. Cancer and other therapeutic areas. 10-14 September 2006, San Francisco, CA, USA.
Perry
Letitia
L
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. letitia.perry@thomson.com
Balfe
Andrew
A
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002621:Chemistry; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy; D006727:Hormone Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010121:Oxytocin / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000627:therapeutic use; D012958:Societies, Scientific; D014481:United States; D000520:alpha-Glucosidases / Q000235:genetics / Q000627:therapeutic use
D047228:Angiotensin II Type 1 Receptor Blockers; D018927:Anti-Asthmatic Agents; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D065128:Endothelin Receptor Antagonists; D006727:Hormone Antagonists; D011994:Recombinant Proteins; D010121:Oxytocin; C509951:GAA protein, human; D000520:alpha-Glucosidases